...
首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Novel amide derivatives as inhibitors of histone deacetylase: design, synthesis and SAR.
【24h】

Novel amide derivatives as inhibitors of histone deacetylase: design, synthesis and SAR.

机译:作为组蛋白脱乙酰基酶抑制剂的新型酰胺衍生物:设计,合成和SAR。

获取原文
获取原文并翻译 | 示例
           

摘要

Enzymatic inhibition of histone deacetylase (HDAC) activity is emerging as an innovative and effective approach for the treatment of cancer. A series of novel amide derivatives have been synthesized and evaluated for their ability to inhibit human HDACs. Multiple compounds were identified as potent HDAC inhibitors (HDACi), with IC(50) values in the low nanomolar (nM) range against enzyme activity in HeLa cell extracts and sub-microM for their in vitro anti-proliferative effect on cell lines. The introduction of an unsaturated linking group between the terminal aryl ring and the amide moiety was the key to obtain good potency. This approach yielded compounds such as (E)-N-[6-(hydroxyamino)-6-oxohexyl]-3-(7-quinolinyl)-2-propenamide (27) (HDAC IC(50) 8 nM) which showed potent in vivo activity in the P388 mouse leukemia syngeneic model (an increased lifespan (ILS) of 111% was obtained).
机译:对组蛋白脱乙酰基酶(HDAC)活性的酶抑制作用正在成为一种创新且有效的癌症治疗方法。合成了一系列新型酰胺衍生物,并评估了它们抑制人HDAC的能力。多种化合物被确定为有效的HDAC抑制剂(HDACi),其IC(50)值在低纳摩尔(nM)范围内对HeLa细胞提取物和亚microM中的酶活性具有抗体外增殖作用。在末端芳基环和酰胺部分之​​间引入不饱和连接基团是获得良好效能的关键。这种方法产生的化合物如(E)-N- [6-(羟基氨基)-6-氧己基] -3-(7-喹啉基)-2-丙烯酰胺(27)(HDAC IC(50)8 nM)显示出有效P388小鼠白血病同基因模型中的体内活性(获得的寿命增加(ILS)为111%)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号